Abstract
6315-S (flomoxef), a new oxacephem parenteral antibiotic, has broad spectrum activity against Gram-positive and Gram-negative bacteria, and stronger activity against Grampositive bacteria than latamoxef (LMOX). Basic and clinical studies on 6315-S were performed, and the following results obtained.
Concentrations of 6315-S in venous serum, uterine arterial serum, uterus (portio, cervix, myometrium and endometrium), oviduct and ovary were measured in 4 patients after 30 min drip infusion of 1g, and in 2 cases after 60 min drip infusion of 1 g. Concentration of 6315-S in pelvic dead space exudate was measured in 4 patients after 30 min drip infusion of 1g. These concentrations were higher than MIC's of 6315 -S against most organisms, and showed good penetration into tissues.
Four patients, one each with puerperal endometritis, puerperal fever, pyometra and infectious lymphocyst, aged 28-81 years, and with a body weight of 49-69.5kg, were treated with 6315-S, mainly with 1 g b. i. d. drip infusion for 5-8 days. The overall clinical efficacy was good in 3 patients, and poor in 1, the efficacy rate being 75.0%, and the bacteriological effect was eradication in 1, and decrease in 2. No side effects or abnormal laboratory findings were noted.
